Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07409181 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 405
- Enrollment target
NCT07409181: Recruiting Phase 2 study, sponsored by Boehringer Ingelheim.
NCT07409181 is a Phase 2 study that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 405 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07409181, a Phase 2 study, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 405 participants
- Enrollment target
Study Summary
This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.
Interventions
- DRUG Placebo
- DRUG BI 3000202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2029-07-08 |
| Phase | Phase 2 |
What NCT07409181 shows while recruiting
NCT07409181 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07409181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07409181 about?
NCT07409181 is a clinical study titled "A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)". This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are pu...
What is the current status of trial NCT07409181?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2026-04-20. Estimated completion is 2029-07-08.
What interventions are being tested in trial NCT07409181?
The interventions under investigation include: Placebo (DRUG), BI 3000202 (DRUG).
Who is sponsoring clinical trial NCT07409181?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07409181's enrollment target sits among peer trials
405 95th of 2000 higher than 1,906 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI